Therapeutic Index

Each Tablet contains:
Glimepiride and Metformin Hydrochloride Extended Release Tablets

COMPOSITION :
GLUCORIDE-GL 501
Each tablet contains
Glimepiride………………..…………………………………………..1 mg
Metformin Hydrochloride extended-release…………………....500 mg

GLUCORIDE-GL502
Each tablet contains
Glimepiride……………….. ………………………………………….2 mg
Metformin Hydrochloride extended-release …………………...500 mg
 

INDICATIONS :
Glucoride-GL is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes who are already treated with a combination of glimepiride and metformin or whose diabetes is not adequately controlled with metformin alone, or for those patients who have initially responded to glimepiride alone and require additional glycaemic control.

DOSAGE AND ADMINISTRATION :
General
Dosage should be individualized on the basis of both effectiveness and tolerance. The combination should be given once daily with meals and should be started at a low dose. The initial recommended dose is one tablet once daily with breakfast or first main meal of the day.

Starting dose for patients inadequately controlled on metformin monotherapy

Based on the usual starting dose of glimepiride (1-2 mg daily), Glucoride Gl 501 or Glucoride Gl 502 may be initiated once daily, and gradually titrated after assessing adequacy of therapeutic response.

Starting dose for patients who initially responded to glimepiride monotherapy and require additional glycaemic control

Based on the usual starting doses of metformin extended release (500 mg once daily), Glucoride Gl 501 or Glucoride Gl 502 may be initiated once daily, and gradually titrated after assessing adequacy of therapeutic response .

CONTRAINDICATIONS :
Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ³ 1.5 mg/dL [males], ³ 1.4 mg/dL [females] or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicaemia.

Congestive heart failure requiring pharmacologic treatment.

Known hypersensitivity to this product or any of its components.
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.

Patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function

PACKAGING INFORMATION :
Glucoride-GL 501 ...............................Strip of 10 tablets
Glucoride-GL 502 ...............................Strip of 10 tablets

Wallpapers :         
CLICK ON PHOTO TO SEE LARGE.